Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 228

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 228
---
 times will likely pay different prices for those shares, and so may experience different levels of dilution and, in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Shareholder in this offering as a result of future sales made by us to the Selling Shareholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Shareholder under the SEPA, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Shareholder may make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price.

Because the purchase price per share to be paid by the Selling Shareholder for the common shares that we may elect to sell to the Selling Shareholder under the SEPA, if any, will fluctuate based on the market prices of our common shares during the applicable pricing period, as of the date of this prospectus we cannot reliably predict the number of common shares that we will sell to the Selling Shareholder under the SEPA, the actual purchase price per share to be paid by the Selling Shareholder for those shares, or the actual gross proceeds to be raised by us from those sales, if any. As of February 10, 2025, there were 11,816,721 our common shares outstanding. If all of the 7,500,000 common shares offered for resale by the Selling Shareholder under the registration statement that includes this prospectus and the 1,890,000 common shares as of the date of this prospectus offered pursuant to the Prior Registration Statement were issued and outstanding as of such date (without taking into account the 4.99% Ownership Limitation), such shares would represent approximately 80% of the total number of our common shares outstanding as of February 10, 2025.

Although the SEPA provides that we may, in our discretion, from time to time after the date of the SEPA and during the term of the SEPA, direct the Selling Shareholder to purchase common shares from us in one or more Advances under the SEPA, for a maximum aggregate purchase price of up to $15,000,000, only 7,500,000 common shares (105,840 of which represent the Commitment Shares we issued to the Selling Shareholder pursuant to the SEPA as payment for